|
|
||||||||
From the Institute of Neurological Science, University of Catania, Italy.
Address correspondence and reprint requests to Dr. A. Nicoletti, Istituto di Scienze Neurologiche, Università di Catania, Via Santa Sofia 78, 95125 Catania, Italy; e-mail: anicol{at}dimtel.nti.it
| Article Abstract |
|---|
|
|
|---|
METHODS: The authors studied the frequency of MS in the community of Catania in a population of 333,075 inhabitants according to the 1991 census. The primary sources for the case ascertainment were the neurologic and motor rehabilitation departments, the MS Center, the Italian MS Association, private neurologists, and family doctors. All patients who satisfied the Poser criteria for clinically definite MS, laboratory-supported definite MS, clinically probable MS, and laboratory-supported probable MS were considered prevalent and incident cases.
RESULTS: One hundred ninety-five patients with MS who had had the onset of disease on prevalence day in a population of 333,075 inhabitants were detected. The prevalence rate was 58.5 per 100,000 (95% CI 50.7 to 67.5). Prevalence was higher in women (62.0/100,000) than in men (54.8/100,000). The age-specific prevalence showed a peak in the group aged 35 to 44 (145.1/100,000). From 1975 to 1994, 170 subjects with MS had the clinical onset of the disease. The mean annual incidence was 2.3 per 100,000 (95% CI 2.0 to 2.6). Age-specific incidence showed a peak in the group aged 25 to 34 (6.32/100,000). Incidence for 5-year intervals increased from 1.3 during 1975 to 1979 to 3.9 during 1990 to 1994.
CONCLUSIONS: These prevalence and incidence rates are close to those reported in other similar surveys carried out in Italy and southern Europe.
| Introduction |
|---|
|
|
|---|
| Methods. |
|---|
|
|
|---|
|
All surviving potential patients with MS identified from these sources, except the patients with MS followed in our neurologic department and MS center, were called to undergo neurologic examination performed by trained neurologists of our team to confirm the diagnosis. When transportation was difficult, trained neurologists examined the potential patients with MS at home. For deceased patients, close relatives were interviewed.
Considering a mean length of time from onset to diagnosis of 5 years, we analyzed all the sources up to 1999 to detect the patients who had the clinical onset of disease before the prevalence day but fulfilled the diagnostic criteria adopted only after the prevalence day. We verified all the sources at least twice.
All existing records were manually reviewed. To minimize potential sources of error during the data collection, we selected a team of neurologic interns who spent at least 1 month at the MS center and who were previously trained for data abstraction. Information was collected on precoded forms created ad hoc and revised by a supervisor. Data were double entered into a computer using the Epi-Info version 6 package.8 Data were checked for consistency, and any errors were corrected.
Diagnostic criteria. In our study, we adopted the diagnostic criteria of Poser et al.9 All patients who satisfied these criteria for clinically definite MS (CDMS), laboratory-supported definite MS (LSDMS), clinically probable MS (CPMS), and laboratory-supported probable MS (LSPMS) were considered as prevalent and incident cases. The date of clinical onset was defined as the date when a patient first noticed a clear symptom of MS on the basis of the list of onset symptoms proposed by Poser in 1995.10 When available, the onset was established using objective data, or the history was obtained by interviewing patients and their close relatives. Patients with isolated retrobulbar optic neuritis were excluded from the study.
Prevalence was based on the number of patients who were living in the study area on January 1, 1995 (prevalence day) and had the clinical onset while living there (onset-adjusted prevalence rate). Crude prevalence rate was age adjusted to the world standard population11 and to the Italian population (national census 1991).7 To allow international comparison, we also calculated the prevalence rate considering only patients who fulfilled the diagnostic criteria on the prevalence day. Moreover, we calculated the onset-adjusted prevalence rate considering only the defined cases and not the probable ones.
Incidence was studied from 1975 to 1994 and was based on the year of the clinical onset (onset-adjusted incidence risk). Confidence intervals for estimates were calculated assuming a Poisson distribution.12
| Results. |
|---|
|
|
|---|
Prevalence. On the prevalence day (January 1, 1995), we detected 195 patients with MS (87 men and 108 women) who were resident in the study area and who had experienced the clinical onset of the disease. According to Posers diagnostic criteria, of these 195 prevalent patients, 173 were classified as CDMS, 3 as LSDMS, and 19 as CPMS.
The onset-adjusted prevalence rate (195 cases with onset before the prevalence day) was 58.5 per 100,000 (95% CI 50.7 to 67.5). Age-adjusted prevalence to the Italian population (census 1991) was 55.4 per 100,000 and age adjusted to the world standard population 54.6. Overall, the prevalence was higher in women, 62.0 per 100,000 (95% CI 51.1 to 75.1), than in men, 54.8 per 100,000 (95% CI 44.1 to 67.9).
Taking into account only the 176 cases classified as CDMS and LSDMS, the prevalence was 52.8 per 100,000 (95% CI 39.8 to 68.6), 49.7 for men (95% CI 36.9 to 65.5), and 55.7 for women (95% CI 41.9 to 72.4).
Considering only patients with defined MS at the prevalence day (totally 144 cases), the prevalence was 43.2 per 100,000 (95% CI 30.8 to 58.2), 45.3 for men (95% CI 33 to 60.6), and 41.3 for women (95% CI 29.5 to 56.2).
Analyzing the 195 prevalent patients, age-specific prevalence increased in the first groups of age, with a peak in the group aged 35 to 44 (145.1/100,000), and showed a steep decline in other groups, reaching a rate of 24.8 in the older age groups (65 to 74 years old). Table 1 shows age- and sex-specific prevalence rates per 100,000.
|
Of 195 patients with MS at the prevalence day, 99 (50.8%) presented a relapsingremitting course, 68 (34.9%) a secondary progressive course, and 9 patients (4.6%) a primary progressive course. Nineteen (9.7%) patients were unclassifiable.
The average length of time between the clinical onset and the first relapse (available in only 174 patients) was 34.5 ± 35.4 months, with a median of 24 months and range of 1 to 204 months.
Regarding the initial symptom in our sample, the most common was sensory (60; 30.9%) followed by motor (36; 18.6%), optic neuritis (34; 17.4%), brainstem (21; 10.8%), cerebellar (21, 10.8%), and sphincter disturbance (6; 3.1%). Seventeen (8.8%) had other forms of symptoms at onset.
The scores of Kurtzkes Expanded Disability Status Scale (EDSS)13 show a bimodal distribution with a first peak at 2.5 and the second peak at 6.5. The mean score was 3.6 ± 2.2, and the median was 3. In particular, 61.1% of patients showed either no disability or minimal disability (EDSS 0 to 3.5), 15.9% showed relatively severe disability (EDSS 4 to 5.5), and 23.3% showed severe disability (EDSS > 5.5).
Incidence. From 1975 to 1994, 170 patients (75 men and 95 women) living in the study area had the clinical onset of the disease. Of these, 149 were classified as CDMS, 3 as LSDMS, and 19 as CPMS. The mean age at onset was 29.8 ± 9.9 years (29.7 years for men and 29.7 years for women), ranging from 8 to 59 years; the median age was 28 years.
During the incidence period, the average population was 374,049 (180,257 men and 193,114 women). The average annual onset-adjusted incidence was 2.3 per 100,000 (95% CI 2.0 to 2.6). Incidence for women was 2.5 per 100,000 (95% CI 2.0 to 3.0) and for men 2.1 per 100,000 (95% CI 1.6 to 2.6). Table 2 shows average annual incidence rates for 5-year intervals from 1975 to 1994. The incidence increased from 1.3 during 1975 to 1979 to 3.9 during the last period 1990 to 1994. Incidence was particularly higher in women than in men during the last period 1990 to 1994 (3.2 for men and 4.5 for women).
|
|
|
| Discussion. |
|---|
|
|
|---|
To allow an international comparison, we used the diagnostic criteria of Poser et al.,9 which are widely adopted in surveys performed from 1980, considering in our analysis both defined and probable MS.
Several studies to determine the frequency of MS have been carried out in Europe from 1980 to date. Prevalence in northern Europe (north of 46° latitude) is, on average, higher than those reported in the south, showing rates that can be greater than 100 per 100,000.1 Rates from southern Europe (between 36° and 46° latitude) are on average lower than northern ones, ranging from 26 to 83 per 100,000.1 An exception is the study carried out in the Croatian community of Gorski Kotar, where a rate of 124 per 100,000 was reported in 1986.14 As regards the frequency of MS in Italy, prevalence ranged from 21.5 per 100,000 in Pescara (1990)2 to 143.9 per 100,000 in Sardinia (1991).4 Our crude prevalence of 58.5 per 100,000 (95% CI 50.7 to 67.5) is close to those reported in Valle dAosta in 1985 (38.4./100,000),15 Macerata in 1988 (37.5/100,000),16 Ascoli Piceno in 1988 (42.8/100,000),16 Ferrara in 1993 (69.4/100,000),3 and Reggio Emilia in 1995 (39.44/100,000).17
Four studies were carried out in the center and in the west cost of Sicily during 1975 to 1985, showing rates ranging from 32 to 51 cases per 100,000.18-21 All these surveys investigated smaller populations (not greater than 60,000 inhabitants) and used different diagnostic criteria. A second survey was carried out in Monreale in 1991, showing a higher rate (72.4/100,000) than that reported in 1980 (43/100,000).22 In 1989, an epidemiologic survey was carried out in Catania, reporting a prevalence rate of 12 per 100,000, lower than that of this study.6 Several factors could play a role in these difference rates. In 1989, different diagnostic criteria were used, and only patients with a defined diagnosis of MS at the prevalence day were considered. An improvement in MS diagnosis during the last 10 years may be also due to the more common use of sophisticated diagnostic procedures (MRI) and probably to a greater public awareness of this disease.
In our study, the distribution of age- and sex-specific prevalence is similar to that reported in the literature.
Incidence rates in northern Europe ranged from 0.8 per 100,000 (Hungary) to 7.2 in the United Kingdom. Incidence rates in southern Europe ranged from 1.8 found in Greece (1970 to 1984) to 3.0 in Spain (1986 to 1992).1 Higher rates were found in Sardinia (5.1) and Croatia (5.9).14,23 As reported, these higher values are probably due to a particular ethnic composition of these populations.
Our average annual onset-adjusted incidence was 2.3 per 100,000 (95% CI 2.0 to 2.6), which is close to those reported in other surveys (1.59 Reggio Emilia, 2.1 Valle dAosta, 2.3 Ferrara).2,15,17
Considering the average annual incidence rates for 5-year intervals from 1975 to 1994, incidence increased from 1.3 during 1975 to 1979 to 3.9 during 1990 to 1994.
The increased frequency may be caused by a real change in MS risk but could also reflect improvements in case ascertainment and diagnosis. This last hypothesis is also supported by the fact that the average length of time between the onset and the diagnosis decreased during the study period, from 8.6 during 1975 to 1980 to 1.9 in the last 5-year interval, 1990 to 1995.
| Acknowledgments |
|---|
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
A Nicoletti, F Patti, S Lo Fermo, S Messina, E Bruno, L Raciti, and M Zappia A possible spatial and temporal cluster of multiple sclerosis in the town of Linguaglossa, Sicily: an update Multiple Sclerosis, January 1, 2009; 15(1): 129 - 130. [PDF] |
||||
![]() |
A. Alonso and M. A. Hernan Temporal trends in the incidence of multiple sclerosis: A systematic review Neurology, July 8, 2008; 71(2): 129 - 135. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Granieri, C. Monaldini, R. De Gennaro, S. Guttmann, M. Volpini, M. Stumpo, P. Fazio, and I. Casetta Multiple sclerosis in the Republic of San Marino: a prevalence and incidence study Multiple Sclerosis, April 1, 2008; 14(3): 325 - 329. [Abstract] [PDF] |
||||
![]() |
G. Dean, T. W. Yeo, A. Goris, C. J. Taylor, R. S. Goodman, M. Elian, A. Galea-Debono, A. Aquilina, A. Felice, M. Vella, et al. HLA-DRB1 and multiple sclerosis in Malta Neurology, January 8, 2008; 70(2): 101 - 105. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Hirtz, D. J. Thurman, K. Gwinn-Hardy, M. Mohamed, A. R. Chaudhuri, and R. Zalutsky How common are the "common" neurologic disorders? Neurology, January 30, 2007; 68(5): 326 - 337. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Nicoletti, F. Patti, S. Lo Fermo, V. Sorbello, E. Reggio, D. Maimone, M. Zappia, and A. Reggio Possible increasing risk of multiple sclerosis in Catania, Sicily Neurology, October 25, 2005; 65(8): 1259 - 1263. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.T. Mayr, S.J. Pittock, R.L. McClelland, N.W. Jorgensen;, J.H. Noseworthy, and M. Rodriguez Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985-2000 Neurology, November 25, 2003; 61(10): 1373 - 1377. [Abstract] [Full Text] [PDF] |
||||
![]() |
F Ranzato, P Perini, E Tzintzeva, M Tiberio, M Calabrese, M Ermani, F Davetag, L De Zanche, E Garbin, F Verdelli, et al. Increasing frequency of multiple sclerosis in Padova, Italy: a 30 year epidemiological survey Multiple Sclerosis, August 1, 2003; 9(4): 387 - 392. [Abstract] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |